about
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO studyBiochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.Deep sequencing reveals microRNAs predictive of antiangiogenic drug responsePemetrexed in first-line treatment of non-small cell lung cancer.Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.Quality of life and supportive care for patients with metastatic renal cell carcinoma.Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel.A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) StuExperience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma.Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study.Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection.Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumoursHIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma.Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer.Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.Radium-223 international early access program: results from the Spanish subset.Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer.Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.CT scan prior to radiotherapy in unresectable, locally advanced, non-small cell carcinoma of the lung: is it always necessary?[Abdominal ultrasonography versus abdominal CT in the follow-up of testicular germ cell tumors].
P50
Q30382892-018C463B-9771-4D9E-8346-643761D54563Q30835493-B5461BF7-F097-4FD7-ACCC-CFE56FA03905Q33340182-60FFD23A-9D18-4DC0-A708-FECCA36AAE0DQ34658095-EAE05081-A50C-4E0C-B143-803C52105020Q35180823-0B43AB43-3184-48B9-8662-CD04830761BAQ35274936-DAF02817-E55D-4CFC-8157-A8BBF50DDCB4Q35932363-E5D5877D-CB1C-4C8C-86B6-EEB1981F4B7DQ36614418-CB440BE5-084F-4635-BD2F-C21AC40A9D1FQ36959180-933015CA-CF9F-4D4B-BF05-D1523D25AEF1Q37003299-43F6F575-A813-48F9-A477-4597BD4D91BDQ37277227-717836A2-742B-41A4-8A79-A72B8DD5E9CFQ37408704-F9936DBF-736B-4278-AB2C-E27792FCBA98Q37514211-6C0133B5-64AD-44C9-918E-A37AA0F52333Q37780020-28B8C916-3C57-4BB2-A433-30AEDD221368Q38017587-39C562B1-97F5-452C-B010-E0A9A28EC305Q38189898-878B02B5-93A6-469A-BA05-F2E3129A999EQ38252486-27E868B1-99BD-48E0-B4F4-3EC97D65D5B3Q38655110-8A61287C-EFF9-4C43-9803-E0D551236811Q38768663-EC6133FE-C62D-4575-8AFB-5751867D7DC6Q38950573-BC9E5DAB-6806-480B-BC5B-97E7666EA587Q38999348-C7990C80-3016-446B-BBDA-663BC1E9747DQ39252806-8872EC4E-4543-4FF8-B404-4A06454F2681Q40275218-E83096FC-2328-4134-A81D-E22E4DC05A05Q40523631-4F9C7690-81EF-4E46-ADA6-E221F5D85642Q40549902-E3B0AD22-E655-4C24-9FA5-379486BF757EQ41897121-EF6D3394-047F-444E-B33F-5BF0CB2B7757Q42128311-0ED726DA-C757-41E4-8946-21EAF98C758EQ42315381-3B3D4B85-9EDB-454A-8509-F0ED4E4D9AFAQ42364455-F61F4DB4-F58A-4330-84EC-C7B07DF01696Q43056663-5B57A652-BA36-4C35-ABCA-7F5584D6BC04Q44247719-E8C64830-7CE6-4A9E-B539-3AD3720C7D12Q44260338-7101A700-1BD9-47A5-8180-2838F88F659EQ44633893-C2E0A2C7-BEE1-41C6-B08C-7F38C0A4BE90Q47786425-9ED905AD-E534-4AEB-92E9-2C5AF98BD077Q48613537-575C549B-4204-414D-BC7C-771CA37384DCQ51045506-3E0C6BC3-E25E-4D5F-922B-F03171692EE8Q52586557-679050DE-EC02-46F8-867B-9FEFA7E19557Q52650769-B71B9C53-5ACB-408D-80A8-338EED0F76E6Q52983557-DF1509B5-CF00-47F8-91D5-4C6FB69E73E1Q53221018-073F4015-2ABC-4BE9-BE52-ABCF38B87C69
P50
description
researcher
@en
wetenschapper
@nl
name
E Esteban
@en
E Esteban
@nl
type
label
E Esteban
@en
E Esteban
@nl
prefLabel
E Esteban
@en
E Esteban
@nl
P106
P31
P496
0000-0002-2980-5254